Company Overview

Founded in April 2006, Concert Pharmaceuticals is the first company dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium.

Concert applies its innovative precision deuterium chemistry platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create novel drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense.

The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. Concert expects to initiate its first clinical study in 2008.

Concert is a rapidly growing company with an entrepreneurial culture based in Lexington, Massachusetts. The Company is led by an experienced management team and Board of Directors, and is supported by top-tier venture capitalists and leading crossover funds. Concert has raised $95.5 million since its inception.

[ back to top ]